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The growing body of evidence recognizing the adipose tissue (AT) as an active endocrine
organ secreting bioactive mediators involved in metabolic and inflammatory disorders,
together with the global epidemic of overweight and obesity, rise obesity as a hot topic
of current research.The chronic state of low-grade inflammation present in the obese con-
dition and the multiple pleiotropic effects of adipokines on the immune system has been
implicated in the pathogenesis of several inflammatory conditions including rheumatic
autoimmune and inflammatory diseases. We will discuss the main relevant evidences on
the role of the AT on immune and inflammatory networks and the more recent evidences
regarding the effects of obesity on the incidence and outcomes of the major autoimmune
chronic inflammatory diseases.
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INTRODUCTION
In the last few years, the interest and research in the field of obesity
have esponentially risen, due to its increased prevalence and to the
burden of the obesity-related diseases (1).
Moreover, white adipose tissue (WAT) has emerged as an active
endocrine organ, playing a role not only on metabolism but also
on immune and inflammatory processes by releasing a plethora of
adipocytokines and pro-inflammatory mediators, among which
TNF-α, IL-6, adiponectin, leptin, resistin, visfatin, and C-reactive
protein (2).
The inflammatory role of the adipose tissue (AT), together
with the rise in incidence of autoimmune diseases, has growing
a huge interest in the relationship between obesity and chronic
inflammatory diseases.
Obesity in turn predisposes to metabolic and cardiovascular
diseases, and it is becoming clear that the dietary habits in Western
societies (“too much,”“too fatty,”“too salty”) and a high body mass
index (BMI) constitute risk factors for autoimmune diseases (3).
DEFINITION AND PREVALENCE OF OBESITY IN RHEUMATIC
DISEASES
Overweight and obesity are defined by the World Health Orga-
nization (WHO) as abnormal or excessive fat accumulation that
presents a risk to health (4). BMI was developed as a clinically
measurable approximation for body fat percentage and according
to the National Institute of Health (NIH) classification, BMI was
categorized into three classes, as a BMI <25 Kg/m2, identifying
normal-weight status, BMI 25–30 Kg/m2, identifying overweight
and BMI >30 Kg/m2, identifying obese status (5).
Body mass index is recognized as a valid measure of absolute fat
mass adjusted for height, yet the use of BMI may present some lim-
its. First, the abdominal fat distribution has been suggested being
more stringently associated with cardiovascular risk and with AT
effects, so anthropometric measures such as waist circumference
has been shown to better reflect central or abdominal adiposity
than BMI. Waist circumference is accepted as a clinical measure
of abdominal obesity and has been proposed as substantial indi-
cator of health risk and as a criteria for the metabolic syndrome
(6). Moreover, the accuracy of BMI in estimating the amount of
fat mass may vary according to age, as in the older age the lean
body mass tends to decrease in favor to adipose mass, to gender, as
female had higher proportion of AT, and under some inflamma-
tory disease condition that may alter the body mass composition,
like rheumatoid arthritis (RA).
Indeed, methods allowing for the characterization of body fat
proportion (e.g., dual energy x-RAY absorpsiometry-DXA, bio-
electrical impedence) demonstrated that RA patients have more
body fat for a given BMI than healthy controls; moreover, male
RA patients had more visceral fat and female more subcutaneous
fat compared with controls with similar BMI and waist circum-
ference, so lower BMI cut-offs has been proposed to improve the
predictive value of this indicator in RA (7, 8).
However, at present BMI still remains a valid and easily
evaluable surrogate to estimate total body fat mass in clinical
evaluation (9).
To date, the prevalence of obesity and overweight in autoim-
mune chronic inflammatory diseases (ACIDs) are not exhaustively
reported and may widely varies depending on the populations con-
sidered, the type of disease and the disease duration at the time
of evaluation, because the disease and therapy can modify the
body weight and composition. Overall, the prevalence of obesity
in many rheumatic diseases seems to be similar to slightly higher
than the general population, with the exception of Psoriatic Arthri-
tis (PsA). Figure 1 illustrates the distribution of normal weight,
overweight, and obese subjects in different cohorts of patients with
the most representative inflammatory, autoimmune, and vascular
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FIGURE 1 | Distribution of BMI categories among an Italian cohort of
adult autoimmune disease patients. In our tertiary referral centre, the
prevalence of overweight [defined according to the WHO International
standards as a body mass index (BMI) of 25–29.9] or obesity (BMI ≥30) is
similar between the different autoimmune disease categories. The graph
summarized data from an early-rheumatoid arthritis (early-RA) cohort of
patients (N =401, 76.3% female, mean age: 54.6± 14.0 years, mean BMI of
25.3±4.4 Kg/m2), a Spondyloarthritis (SpA) cohort (N =220, 30.6% female,
mean age: 39.5±11.8 years, mean BMI of 25.1±4.4 Kg/m2), a Systemic
Lupus Erythematosus (SLE) cohort (506 patients, 90.3% female, mean age:
44.1±14.8 years, mean BMI of 24.0±4.6 Kg/m2), a Systemic Sclerosis
(SSc) cohort (442 patients, 88.2% female, mean age: 58.5±14.2 years,
mean BMI of 24.4±4.8 Kg/m2), and a primary Sjogren Syndrome (pSS)
cohort (204 patients, 96.1% female, mean age: 56.4±14.3 years, mean
BMI of 24.3±4.3 Kg/m2) (10). Data are reported as percentage (%) of
normal weight, overweight, and obesity in the different diseases.
rheumatic diseases in our tertiary referral center. In particular, the
prevalence of obesity was 12.4% in patients with early Rheumatoid
Arthritis (ERA), 13.5% in seronegative spondyloarthritis (SpA),
10% in Systemic Lupus Erythematosus (SLE), 10.4% in Systemic
Sclerosis (SSc), and 11.3% in primary Sjogren syndrome (pSS).
OBESITY AND INFLAMMATION
Adipose tissue in normal-weight subjects is composed mostly of
adipocytes, i.e., the mature fat cells, and of the interadipocytes stro-
mal vascular fraction including preadipocytes, i.e., the immature
adipocyte precursors, fibroblasts, endothelial, and immune cells.
Almost the full spectrum of immune cell types, and in particular
macrophages, are represented among these AT-resident immune
cells, and they play important housekeeping functions ranging
from apoptotic cell clearance to extracellular matrix remodeling,
tissue homeostasis maintenance, and angiogenesis (11).
The progressive and excessive fat accumulation that occurs in
obesity leads to substantial changes in the amount and phenotype
of the AT-resident immune cells, with an increasing in number
and activity of some of them (most notably macrophages, mast
cells, neutrophils, and T and B lymphocytes) while reducing oth-
ers, including eosinophils and several subsets of T lymphocytes
[T helper 2 (Th2), Treg, and iNKT cells] (12). This imbalance
contributes to the development of obesity-related local and sys-
temic inflammation and although most types of immune cells are
already present in the AT, their number increases notably with the
progression of obesity.
In particular, in obese status, macrophages are the most abun-
dant cell type infiltrating fat tissue and they polarize from an anti-
inflammatory M2 macrophages pattern toward an inflammatory
(M1) phenotype characterized by secretion of pro-inflammatory
cytokines and expression of nitric oxide synthase sustaining the
process of atherogenesis (13).
The link between metabolism and immunity was further cor-
roborated at the intracellular level, with the main inflammatory
signaling pathway comprising nuclear factor-kB (NF-kB) and
inhibitor of kB kinase-b (IKKB) stimulated in obesity (14). Con-
versely, genetic deletion of IKKB or the inhibition of this path-
way by salicylates was shown to attenuate insulin resistance in
both mice and human beings (15). Furthermore, obesity-related
inflammation tends to activate also other pro-inflammatory fac-
tors including the group of c-Jun N-terminal protein kinases
(JNK), while the ablation of JNK protects experimental animals
from diet-induced obesity and inflammation (16).
Nowadays, there is a growing body of evidence that AT is
a dynamic endocrine organ that releases several bioactive sub-
stances, secreted by adipocytes and adipose-resident macrophages,
including some pro-inflammatory cytokines, in common with
inflammatory diseases such as RA, like TNF-α and IL-6, and
specific cytokines, termed “adipokines,” most of which with pro-
inflammatory properties accounting for a chronic low-grade sys-
temic inflammation. Of note, these chronic inflammatory signals
can have a profound impact on CD4+ T cell populations, and
it has been shown, in murine studies, that diet-induced obe-
sity can impact specific fat-resident regulatory T cells (Treg) and
particularly promote a Th17-biased immunity, partly dependent
on IL-6.
The final picture appears to be characterized by an imbalance
between Th1 and Th2 stimuli in fat, perhaps through the deple-
tion of Th2 and AT Treg cells, the increase in CD8+ and Th1 cells
or both. In addition, adipocytes were found to potently activate
T-cells in an antigen- and contact-dependent manner that was
enhanced in obesity, and MHCII-deficiency attenuated inflam-
matory and metabolic responses (17), and many studies have
confirmed that the polarization state of an AT macrophages (ATM)
correlates well with insulin resistance (18).
Of note, in a mouse model of collagen-induced arthritis with a
diet-induced obesity, obese mice had an increased risk of develop-
ing arthritis and a more severe arthritis than lean mice. Although
obesity does not display a pathogenic role in initiating arthritis, it
could play an important role in amplifying the inflammation of
arthritis through the Th1/Th17 response (19).
ADIPOKINES AND INFLAMMATION
Since the identification of leptin as the first bioactive molecule
produced by AT, a growing body of data has accumulated about
the plethora of adipokines produced by WAT (pre-adipocytes and
mature adipocytes, as well as infiltrated macrophages), as the
major contributors to the low-grade inflammatory state associated
with obese condition.
The adipokine family has pleiotropic functions, mediating both
endocrine and immune effects on multiple organs, most of which
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promoting metabolic dysfunctions and inflammatory responses.
The association between obesity and chronic inflammation has
introduced the idea that adipokines may contribute to the patho-
genesis of several inflammatory conditions including rheumatic
diseases, contributing to the complex network of inflammatory
cascade (20, 21).
The role of adipokines in the mechanisms of rheumatic autoim-
mune diseases is supported by evidences that they exert potent
modulatory actions on target tissues involved in rheumatic dis-
eases including synovial, cartilage, bone, and immune cells. On
the other hand, even if adipokines are produced predominantly
by AT, they might also be expressed in the joints by chondrocytes,
synoviocytes, and immune resident cells (22).
The characteristics and effects of more common adipokines
are yet extensively described (23). Here, we briefly summarize the
stronger evidences in understanding the role of the most rele-
vant and most widely studied adipokines, i.e., adiponectin, leptin,
resistin, visfatin, in the complex network of chronic inflammatory
states and autoimmune rheumatic diseases.
ADIPONECTIN
Adiponectin is almost exclusively secreted by adipocytes and
show anti-inflammatory, insulin-sensitizing, and anti-atherogenic
properties (24). Obese people displayed low adiponectin plasma
levels, suggesting that functional adipocytes in lean subjects pro-
duce high adiponectin levels, while in the dysfunctional adipocytes
of obese individuals its expression is down-regulated.
On the side of inflammation, several “anti-inflammatory
effects” of adiponectin have been reported. It modulates the activ-
ity of immune innate response by inducing the production of
relevant anti-inflammatory factors such as IL-1 receptor antago-
nist and IL-10, suppresses TNFα production, promotes the anti-
inflammatory M2-phenotype macrophages polarization; also on
adaptive immunity, adiponectin acts as a potent modulator of both
B and T cells (25).
While in metabolic diseases, the role of adiponectin is clearly
anti-inflammatory in rheumatic inflammatory diseases and its
role is controversial. Unexpectedly, accumulating evidences on RA
found that adiponectin was elevated in RA serum and synovial
fluid, it is strongly expressed also at the sinovium level, directly
correlate with disease activity and radiologic progression and it
seems not affected by TNF blockade (26).
LEPTIN
The adipokine leptin, the product of the ob gene, is mainly synthe-
sized by WAT and is considered a major regulator of body weight
by suppressing appetite, thus decreasing food intake, and stimulat-
ing energy expenditure. However, leptin plasma levels are directly
correlated with the amount of body fat and obese people have
high circulating leptin levels, indicating a resistance to its action
in obese status (27).
Leptin is considered a pro-inflammatory cytokine, as its
synthesis is enhanced during acute infection and inflamma-
tion, as well as under the action of inflammatory mediators
such as TNFα, IL-6, and IL-1 (28). Furthermore, leptin itself
stimulates the production of pro-inflammatory cytokines from
macrophages and increases the production of Th1 type cytokines,
thus polarizing the Th1/Th2 balance toward a Th1 phenotype
(29, 30).
Despite its pro-inflammatory profile, data on the role of leptin
in RA remain controversial. In fact, there are studies with conflict-
ing results regarding differences in circulating leptin levels between
RA patients and controls and the association of leptin levels with
disease activity (31), even if leptin seems to have a protective role
against bone damage (32), as well as in animal models it is not
clearly defined whether leptin has inducing or attenuating effects
on arthritis development and severity (33).
RESISTIN
Resistin was initially thought related to insulin resistance studies in
animal models; although evidence for this effect in human beings is
less clear (34). Even if resistin production was originally described
to be restricted only to WAT, subsequently it was observed that in
human beings resistin mainly derives from circulating monocytes
and macrophages (35), suggesting a major role in inflammatory
processes in human beings.
In this regard, several studies demonstrated that resistin expres-
sion is up-regulated by pro-inflammatory cytokine, and in turn,
resistin is able to stimulate the production of TNFα, IL-6, IL12
TNF-α, IL-1β, and resistin itself (36). These evidences, together
with the finding that the injection of resistin into mice joints
triggers synovitis, highlight a potential role of resistin in the
inflammatory cascade of inflammatory arthritis (36). In fact, in
RA, serum, and synovial fluid resistin levels were higher than in
osteoarthritis, as well as resistin expression in synovial lining lay-
ers. Moreover, resistin levels positively correlated with acute phase
reactants and RA disease activity and seem modulated by anti-TNF
therapy (37).
VISFATIN
Visfatin, initially named pre-B-cell colony-enhancing factor, is
an adipokine with insulin-mimetic actions, preferentially pro-
duced by visceral AT (38). Circulating levels of visfatin correlates
with the amount of visceral fat and are increased in patients
with obesity and type-2 diabetes and are reduced after weight
loss (39).
Like resistin, visfatin is synthesized also in response to inflam-
matory stimuli and, on the other hand, it can enhances pro-
duction of TNF-α, IL-6, IL-1β, as well as of IL-10 and IL-1Ra
(40). Additionally, it promotes activation of T cells by enhanc-
ing the expression of co-stimulatory molecules, such as CD40,
CD54, and CD80, on monocytes, acts as a chemotactic factor
on monocytes and lymphocytes and it strongly affects the devel-
opment of both T- and B-lymphocytes. As in other inflamma-
tory conditions, in RA circulating levels of visfatin are increased,
as well as its expression in synoviocytes at sites of attachment
and invasion into cartilage or bone. In agreement with these
findings, it is the association between radiographic damage and
high visfatin serum concentrations. Visfatin serum and synovial
fluid levels correlated with the degree of inflammation, with
the severity of the disease, and with joint damage. Moreover,
inhibition of visfatin in collagen-induced arthritis mice reduced
arthritis severity with similar effect to that produced by TNF-α
inhibitor (41).
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PEDF AND CHEMERIN AS INFLAMMATORY ADIPOKINES IN
OBESE PATIENTS WITH AUTOIMMUNE DISEASES
The adipokine family is continuously growing and among the
emerging adipokines, pigment epithelium-derived factor, and
chemerin seem to be key players in linking obesity and inflam-
mation in rheumatic diseases.
Pigment epithelium-derived factor (PEDF or SERPINF1) has
been described as one of the new adipokines involved in the
development of obesity-related disease. PEDF is a 50 kDa secreted
glycoprotein, member of the serpin (serine protease inhibitor)
family lacking the serine-reactive loop and thus has no function
on protease inhibition (42, 43). The PEDF protein was originally
identified in retinal cell culture supernatants and characterized
as a neurotropic factor (44), but recently, it has been associated
with anti-tumor effects based on its anti-angiogenesis and pro-
apoptosis activities (45). On the other hand, PEDF leads to insulin
resistance and inflammatory signaling in several cell types (46–48).
The SERPINF1 gene is expressed in AT, liver, and bone mar-
row in human beings. Although the circulating levels of PEDF are
thought to derive from the liver (49), to date it is well demonstrated
that PEDF is up-regulated during adipogenesis and is mostly pro-
duced by mature adipocytes, suggesting that AT contributes to
plasma PEDF levels (50, 51). This notion is consistent with studies
indicating that PEDF is one of the most abundant protein secreted
by human adipocytes or from human mesenchymal stem cells (48,
52). This direct association between serum PEDF levels and cen-
tral obesity or the other components of the metabolic syndrome
was well documented (47, 53–55).
Furthermore, in genetically and diet-induced obese mice, AT
PEDF expression and plasma PEDF levels increased up to three-
fold whereas liver and skeletal muscle expressed only low amounts
of PEDF, which did not increase upon obesity. In caloric restric-
tion diet-induced obese mice, a reduction in AT PEDF expression
was demonstrated (46).
In addition to its role in neurogenesis and angiogenesis, PEDF
induces inflammatory signals in several cell lines and circulating
PEDF levels correlate with the inflammatory burden and vascular
dysfunction in individuals with type 1 diabetes (45, 52).
Consistent with this notion, the pathophysiology of obesity is
characterized not only by the increased expression of inflamma-
tory cytokines such as interleukin (IL)-6 and tumor necrosis factor
(TNF)-α but also by the higher expression of PEDF and long-term
obesity may inhibit regulatory responses resulting in a systemic
pro-inflammatory state. Little is known about the regulation of
PEDF expression and secretion but there is evidence of a possible
involvement of hypoxia in human adipocytes (56).
Moreover, Chavas et al. demonstrated that PEDF directly acti-
vates inflammatory signaling proteins, p38 MAPK and ERK1/2,
in macrophages, and activation of these inflammatory kinases
was required for PEDF-mediated macrophage activation (57). In
addition, PEDF mediates activation of pro-inflammatory signal-
ing proteins, p38 MAPK and NF-κB, in muscle and fat cells in
culture. Although PEDF has been considered as a major factor
in the adipocyte culture contributing to macrophage activation,
it is plausible that other factors, such as IL-1 or adipokines, may
also lead to macrophage activation and synergistically enhance
TNF release (48). On the contrary, the protein deacetylase sirtuin-
1 (SirT1) plays a role in the repression of inflammation in
AT, via suppression of JNK and NF-kB signaling disrupting
adipocyte-macrophage communication (58, 59).
The inflammatory milieu of obesity is complex, featuring a
panoply of elevated plasma and tissue specific cytokines that are
increased in some rheumatic diseases and are able to increase
the expression of inflammatory cytokines, such as TNF and IL-
6, also in the early phases of the disease. Moreover, obesity is
associated in some studies with an increased risk of rheumatic
diseases (60, 61); and recent reports have showed a negative asso-
ciation between high BMI and response to anti-TNF agents in
both RA and SpA (62–64), suggesting that fat mass may affect the
response to biologic agents. Pathophysiological mechanisms by
which BMI influences anti-TNF biological drugs response remain
still unclear.
To support the possible role of PEDF as a player in inflamma-
tory burden of RA, we observed that the circulating PEDF levels,
evaluated in a cohort of patients with early RA at the time of RA
diagnosis, are higher in obese and overweight than in normal-
weight subjects and correlated with systemic inflammation (ESR
and CRP) (65).
In recent years, another adipokine, named chemerin, has
emerged has a key adipokine involved in inflammation and
immune responses in RA. Chemerin is involved in adipogenesis,
chemotaxis, and activation of dendritic cells and macrophages. In
healthy conditions, the overweight and obese subjects have higher
levels of circulating chemerin compared to normal-weight sub-
jects, which decrease after reduction of fat mass as a result of a
dietary route (66, 67).
Chemerin is found in inflamed tissues and biological fluids
of different inflammatory diseases, such as RA. Recent studies
have shown that synovial fibroblasts (FLSs) of RA patients express
chemerin and its receptor (ChemR23) and that circulating levels
of this molecule directly correlate with disease activity (68, 69).
The expression of ChemR23 on RA fibroblasts and chemerin itself
activate FLSs to enhance the production of IL-6 and CCL2 (70–
72). Therefore, these observations indicate that chemerin may be
involved in the enhancement of local pro-inflammatory cytokine
and chemokine production by RA FLSs, leading to persistent
amplification of inflammation in the RA synovium, possibly in
an autocrine or paracrine manner. Recently, Ha et al. found that
chemerin levels directly correlate with disease activity in RA (73).
However, it is not yet completely clear whether the circulating
levels of chemerin in patients with RA are more associated with
systemic inflammation or AT itself, but it is confirmed its role as a
biomarker of disease activity.
In this regard, adipokines, i.e., PEDF and chemerin, may pro-
vide a metabolic link between obesity and RA or other autoim-
mune diseases, and as such they could be possible biomarkers of
the effect of weight loss and of the decreased fat tissue in chronic
inflammatory diseases. In fact, new evidences has emerged to sug-
gest that weight loss may lead to an improvement of quality of life
and a reduction of inflammation and of systemic inflammatory
mediators in patients with obesity and RA after weight loss and
metabolic control with a dietary intervention.
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IMPACT OF OBESITY ON AUTOIMMUNE CHRONIC
INFLAMMATORY DISEASES
RA AND OBESITY
Obesity in RA was found prevalent in 18–31% of patients,
overall slightly higher than in the general population. An over-
weight condition has been noted in more than 60% of RA
patients (74, 75).
RA incidence
In the past years, several studies evaluated the impact of obe-
sity on RA incidence, but with inconclusive results, probably
due to small size number of patients included and to the low
prevalence of obesity (61, 76–78). More recently, a large retro-
spective case–control study showed that obesity is associated with
a modest risk of developing RA (OR:1.24; 95% CI: 1.01, 1.53
adjusted for smoking status), but about 50% of the increasing
incidence of RA among this population from Minnesota could be
attributed to the obesity and this effect is more pronounced in
woman (79).
Moreover, data from three different cohorts of patients seem
to indicate that obesity is associated with a likelihood of develop-
ing a seronegative RA, with an OR between 1.6 and 3.45 (78, 80,
81). In particular, in a large Swedish case–control study, dividing
patients according to the ACPA (anti-citrullinated protein anti-
body) positivity, the RA risk linked to obesity appears different
between genders; in fact, only the female gender was associated
with the occurrence of ACPA-negative RA and there was no asso-
ciation between obesity and ACPA-positive RA among women,
while an inverse association between BMI and ACPA-positive RA
was seen in men (80).
In a recent study involving two large prospective cohorts of
women (Nurses’ Health Study-NHS 109,896 woman and Nurses’
Health Study II-NHSII, 108,727 woman, with 1,181 incident cases
of RA), Lu et al. observed a significant association between being
overweight and obese and developing RA, both in seropositive and
seronegative subset. This association was even stronger among
women diagnosed at younger ages, i.e., ≤55 years, with a 35%
increased risk of developing RA, and an almost 50% increased risk
of developing seropositive RA in adulthood. Interestingly, also the
“exposure time”to obesity seems to influence the RA risk in woman
aged 55 or younger with a 37% increased risk of RA with a history
of 10 years of being obese (82).
RA activity and severity
Considering the effects of obesity on RA activity and severity, pub-
lished data suggest a negative influence of a high BMI on disease
activity. In a large cohort of early RA followed-up for an average of
9.5 years, at the study inclusion obese subjects had slightly higher
HAQ, VAS pain and global health scores than patients with a BMI
<30,with similar DAS28 and systemic inflammatory indexes (ESR,
CRP). In the same cohort, at the last follow-up, obese people had
a more active and severe disease, with a decreased probability of
being in disease remission and of reaching sustained remission,
despite similar use of DMARDs, steroids, and biologic drugs in
different BMI groups (83). The association between worst dis-
ease activity and disability was confirmed also in other cohorts of
patients with established RA (84, 85).
In a sub-analysis of the BeST study evaluating the effects of a
BMI >25 on response to therapy in patients with early RA (dis-
ease duration <3 years) naïve to DMARDs, subjects with a BMI
under or over 25 had no differences in baseline DAS, inflam-
matory parameters, HAQ, pain, and global health assessment
(86). In our cohort of 346 early RA with symptoms duration
<12 months, we observed that disease activity indexes (DAS and
DAS28) were higher in obese and overweight patients compared
to normal-weight patients (87).
Regarding disability, like in the general population, worsening
functional capacity and quality of life has been linked to increased
fat mass and, both in the general population and in patients with
RA, pain prevalence, and severity have been linked to obesity; pain
in RA has a large impact on self-reported health, physical function,
and disease activity index (88, 89).
Moreover, it can be hypothesized that adiposity may influence
also the evaluation of swollen joint, but Caplan et al. showed that
the swollen joint count performs in obese subjects at least as well
as in subjects with lower BMI (90). Moreover, as previously dis-
cussed, the worst disease activity and severity in obese RA patients
can be derived from the close association of obesity with activation
of pro-inflammatory pathways.
Despite the evidences of a more severe disease, data on radi-
ographic progression suggest that obesity may be protective
against joint damage (91–94). Studies in patients with early RA, of
up to 3-year duration, suggest that the protective effect of high BMI
seems to be present before the diagnosis of RA, with overweight
and obese RA patients exhibiting less joint damage than their
normal-weight counterparts at the time of diagnosis; this effect
appears to continue during the first years of RA, with joint dam-
age progressing less rapidly in obese than in normal-weight RA
patients (94). The possible reasons for this finding may include an
increase mechanical load stimulating bone synthesis, as suggested
for the protective effect of obesity from osteoporosis development
in the general population, a lower joint destruction in seronega-
tive RA, the RA subset more associated with obesity, higher levels
of estrogens found in obese subjects, having a bone protective
effects, and role of adipokines, in particular adiponectin. As pre-
viously discussed, adiponectin might induce disease activity in
the joint, resulting in more active disease in lean having higher
adiponectin levels and less active in obese patients that displayed
lower adiponectin levels (95). However, this finding has to be
further clarified.
Obesity and RA response to therapy
Regarding the impact of high BMI on response to RA treat-
ments, all the published studies showed that obesity represents
an additional risk of poor response to therapy and of not reach-
ing remission. In first studies conducted on long standing RA,
obese patients were 50% less likely to obtain disease remission
after 12 months of a first-line anti-TNF treatment than normal-
weight subjects, and the worst outcome was observed with the
weight-dosed drug, i.e., infliximab (62, 63, 96).
Similar results were confirmed by observational studies includ-
ing early-RA patients, in whom both obesity and overweight confer
a lower chance to obtain remission or low disease activity, irrespec-
tive of treatment with DMARDs or anti-TNF therapy (86, 97, 98).
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Moreover, more than twice overweight and obese subjects
with Early-RA needed anti-TNF therapy after 12 months from
diagnosis, compared to normal-weight patients (87).
The reason why obesity affects the RA outcomes, in particular
in patients treated with infliximab needs to be clarified. Mech-
anisms that can be postulated are a direct influence of obesity
on drug pharmacokinetics and an inflammatory and therapy-
resistant state induced by AT by the release of specific adipocy-
tokines that are increased in RA patients and are able to increase
the expression of inflammatory cytokines, such as TNF and IL-6.
In this regard, however, studies testing the effect of TNF blockade
on adipokine plasma levels in patients with RA are not conclu-
sive, and the majority of the studies show that anti-TNF drugs
have no influence on the levels of adipocytokines (99). However,
the AT may be associated with an induction of resistance to all of
the anti-TNF drugs, and understanding its role requires further
research. Regarding infliximab, it has recently been shown that Fc
receptors modulate the efficacy of infliximab both in vitro and ex
vivo, whereas the presence of this receptor has no impact on the
inhibitory activity of certolizumab-pegol, which lacks the Fc frag-
ment (100). These data could be helpful in the light of the fact that
omental adipocytes show high expression of Fc receptors (101).
SpA AND PsA AND OBESITY
Seronegative SpA are a heterogeneous group of inflammatory dis-
eases including ankylosing spondylitis (AS), PsA, inflammatory
bowel disease associated SpA (EnteroSpA), and undifferentiated
SpA (USpA), sharing some clinical characteristics, in particular
the involvement of axial spine. At present, only a very few stud-
ies has evaluated the impact of body weight on SpA, focusing
on axial involvement. In a cohort of 155 patients affected by AS
starting treatment with Infliximab at the dosage of 5 mg/Kg, Otta-
viani et al. reported that the response to therapy (BASDAI50) at
6 months was significantly lower in obese (26.5%) than in normal-
weight (77.6%) individuals (64). In another study involving 170
patients affected by a form of SpA with axial involvement treated
with a first-line anti-TNF therapy, the proportion of axial SpA
patients reaching the BASDAI50 after 12 months fell from 72.8%
in normal weight to 54.5% in overweight and 30.4% in obese sub-
jects (102); the lower response rate according to BMI was obtained
under Infliximab treatment.
Psoriatic arthritis, although part of the SpA group, deserves
a separate discussion. More extensive studies are available on
PsA and psoriasis, conditions associated with a high prevalence
of metabolic syndrome and other metabolic disorders. Both PsA
and psoriasis has been associated with an enhanced prevalence of
obesity and overweight. A recent meta-analysis including 201,831
psoriatic patients on a total of 2.1 million subjects conclude that
psoriatic patients are at significantly higher risk of obesity com-
pared with the general population, with an OR from 1.46 for
patients with mild psoriasis to 2.23 for severe-psoriasis (103).
Bhole et al. evaluating patients with PsA, psoriasis, and RA,
found that in all these conditions mean BMI and prevalence of
obesity were higher compared to the general population, in which
BMI was 26.1 and obese people 18%. Interestingly, BMI values
were similar between RA and psoriasis patients, while PsA patients
have higher BMI values than those with psoriasis or RA (29.6, 27.9,
and 27.3 Kg/m2, respectively) and the prevalence of obesity was
37% in PsA, 29% in psoriasis, and 27% in RA (104).
The effects of these two metabolic and autoimmune disorders
are probably bidirectional, as there are evidences supporting that
obesity may be a risk factor predisposing to the development of
psoriasis and PsA, while others suggesting that overweight could
be a consequence of these conditions rather than a predisposing
factor. However, obesity is a well recognized risk factor for the
development of psoriasis and PsA. In a large population of 75,395
individuals with psoriasis, obesity has been associated with a high
risk of incident PsA (105).
Only few studies assessed the relationship between obesity and
the severity of arthritis in patients with PsA. Di Minno et al.
reported that increased BMI predicted less favorable response
to TNFα blockers in patients with PsA who were followed for
24 months (106); and Eder et al. found that overweight and obe-
sity are associated with a lower probability of achieving MDA
among patients with PsA, independently of the use of biological
and non-biological DMARDs (107).
Of particular interest and of crucial clinical relevance is the
effect of weight loss on inflammation and disease outcome. The
few studies evaluating interventions aiming at lowering the body
weight showed significant improvement of psoriasis or PsA sever-
ity, as well as the cardiovascular risk profile in both diseases. Weight
reduction was also associated with improved response to treatment
with TNFα blockers (108–110).
CONNECTIVE SYSTEMIC TISSUE DISEASES: SLE, SSc AND
pSS AND OBESITY
The prevalence of obesity in SLE is between 28 and 50% (111, 112).
Some studies investigated the impact of BMI on SLE, evidencing
conflicting results about a relationship between BMI and the dis-
ease manifestations (113–115). Data from the different cohorts
showed that about two-thirds of patients with SLE were either
overweight or obese but contrasting data have been reported about
an association between overweight and obesity and disease activ-
ity in SLE patients (116). On the other hand, an increased BMI
has shown to be associated with older age, less social support,
depression, poorer self-reported QoL, and fatigue in patients with
SLE (117).
It has been well established that SLE is associated with an
increased risk of cardiovascular disease as compared with gen-
eral population and the Framingham cardiovascular risk score was
significantly higher in SLE women classified as obese compared to
normal-weight patients. Increased waist circumference increases
the risk of atherosclerosis and the incidence of arterial and venous
thromboembolism in patients with SLE (118, 119).
Finally, there was a statistically significant association between
BMI in the SLE patients and the presence of lupus nephritis and
hypertension (120). This is important because hypertension is a
strong risk factor for cardiovascular disease, which is one of the
major causes of death in SLE (121, 122).
The prevalence of obesity in SSc is between 9 and 18%. This
lower percentage of obesity in SSc than in normal population was
observed mainly in women with diffuse SSc, but not in those with
limited SSc (123). In SSc patients, visceral abdominal fat has been
correlated with cardiovascular risk factors and lung functionality,
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as already found in a large population of elderly men and women
(124–126).
Considering that SSc is a form of micro- and macro-vascular
angiopathy the presence of obesity should be regarded as an addi-
tive factor in terms of cardiovascular risk. On the contrary, a
low BMI, together with age ≥65 years, low forced vital capacity
(<50% of the predicted value), clinically significant arrhythmia on
electrocardiogram, absence of anticentromere antibodies, hyper-
tension, chest radiograph suggestive of pulmonary fibrosis, has
been demonstrated to be a predictor of mortality in early SSc (127).
To date, no data are reported about the involvement of obesity
in pSS and its effects. A recent study on a multicentre cohort of
UK pSS patients demonstrated that pain and depression were the
most important predictors of the health-related quality of life in
patients with pSS, accounting for 48% of the variability. More-
over, BMI, fatigue, and anxiety had been identified as significant
predictors, but accounting for <5 of the variability in terms of
EuroQoL-5 dimension utility values (128).
CONCLUSIVE REMARKS
Obesity is a risk factor for many inflammatory and autoimmune
diseases, in terms of incidence, disease severity, and outcomes, as
well as for the overall cardiovascular risk.
Research in the field of obesity and its related effects is contin-
uously growing and the knowledge of these issues has increased
significantly in recent years. Understanding even more deeply the
pathophysiologic mechanisms underlying the interaction between
obesity, inflammation, and disease pathways appears to be of
upmost importance to improve the outcomes in patients with
rheumatic diseases.
This overview provides a rationale for further studies on the
role of AT in RA and the mechanisms behind weight changes
during the course of RA disease, as well as the potential effect of
weight control on the efficacy of medication disease severity, and
complications.
Evaluating the effects of weight loss on the inflamma-
tory/autoimmune disease course appears to be crucial in terms
of potential clinical and also pharmacoeconomics perspectives.
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